Clinical trial
ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
NCT05393791 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- ANZadapt: Phase II Randomised Controlled Trial of Patient-specific Adaptive Versus Continuous Abiraterone or eNZalutamide in Metastatic Castration-resistant Prostate Cancer
- Lead sponsor
- Leiden University Medical Center
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- November 10, 2022
- Completion date
- November 10, 2027
- Enrollment
- 168 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.